Literature DB >> 30025818

Systemic lupus erythematosus-myasthenia gravis overlap syndrome: Presentation and treatment depend on prior thymectomy.

Scott Brian Minchenberg1, Geeta Chaparala1, Zachary Oaks1, Katalin Banki2, Andras Perl3.   

Abstract

In this study, we investigated four patients who met the diagnostic criteria for overlapping systemic lupus erythematosus (SLE) and myasthenia gravis (MG) but responded differently to treatment. All patients were acetylcholine receptor (AChR) and antinuclear antibody positive at the time of SLE diagnosis. Two patients presented with SLE who have been effectively treated with cholinesterase inhibitors for MG. These patients developed SLE with photosensitivity, rash, and arthritis post thymectomy, which had been performed 29 years and 40 years earlier, respectively. Two other patients were found to have AChR antibodies and MG in the context on new-onset SLE. These subjects were responsive to hydroxychloroquine and immunosuppression but failed cholinesterase inhibitors. The evolution of these cases is relevant for the role of thymus in lupus pathogenesis during aging and for treatment selection in SLE-MG overlap patients.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acetylcholine receptor antibody; Antinuclear antibody; Antiphospholipid antibody; Myasthenia gravis; Systemic lupus erythematosus; Thymectomy

Mesh:

Year:  2018        PMID: 30025818      PMCID: PMC6089637          DOI: 10.1016/j.clim.2018.07.007

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  27 in total

1.  Increase of circulating CD4+CD25+ T cells in myasthenia gravis patients with stability and thymectomy.

Authors:  Yi Sun; Jian Qiao; Chuan-Zhen Lu; Chong-Bo Zhao; Xin-Mei Zhu; Bao-Guo Xiao
Journal:  Clin Immunol       Date:  2004-09       Impact factor: 3.969

Review 2.  mTOR activation is a biomarker and a central pathway to autoimmune disorders, cancer, obesity, and aging.

Authors:  Andras Perl
Journal:  Ann N Y Acad Sci       Date:  2015-04-23       Impact factor: 5.691

3.  High prevalence of systemic lupus erythematosus in 78 myasthenia gravis patients: a clinical and serologic study.

Authors:  Zev Sthoeger; Alexander Neiman; Daniel Elbirt; Hiedy Zinger; Eli Magen; Rimona Burstein; Sara Eitan; Jakov Abarbanel; Edna Mozes
Journal:  Am J Med Sci       Date:  2006-01       Impact factor: 2.378

4.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

5.  CD4+ FoxP3+ T regulatory cell subsets in myasthenia gravis patients.

Authors:  Siegfried Kohler; Thomas Oskar Philipp Keil; Sarah Hoffmann; Marc Swierzy; Mahmoud Ismail; Jens Carsten Rückert; Tobias Alexander; Andreas Meisel
Journal:  Clin Immunol       Date:  2017-03-09       Impact factor: 3.969

6.  The MG Composite: A valid and reliable outcome measure for myasthenia gravis.

Authors:  Ted M Burns; Mark Conaway; Donald B Sanders
Journal:  Neurology       Date:  2010-05-04       Impact factor: 9.910

7.  The 1982 revised criteria for the classification of systemic lupus erythematosus.

Authors:  E M Tan; A S Cohen; J F Fries; A T Masi; D J McShane; N F Rothfield; J G Schaller; N Talal; R J Winchester
Journal:  Arthritis Rheum       Date:  1982-11

8.  Clusters of clinical and immunologic features in systemic lupus erythematosus: analysis of 600 patients from a single center.

Authors:  Josep Font; Ricard Cervera; Manuel Ramos-Casals; Mario García-Carrasco; Juan Sents; Carme Herrero; Jose-Antonio del Olmo; Alexandre Darnell; Miguel Ingelmo
Journal:  Semin Arthritis Rheum       Date:  2004-02       Impact factor: 5.532

9.  Impaired regulatory function in circulating CD4(+)CD25(high)CD127(low/-) T cells in patients with myasthenia gravis.

Authors:  Muthusamy Thiruppathi; Julie Rowin; Balaji Ganesh; Jian Rong Sheng; Bellur S Prabhakar; Matthew N Meriggioli
Journal:  Clin Immunol       Date:  2012-10-07       Impact factor: 3.969

10.  Current and emerging therapies for the treatment of myasthenia gravis.

Authors:  Renato Mantegazza; Silvia Bonanno; Giorgia Camera; Carlo Antozzi
Journal:  Neuropsychiatr Dis Treat       Date:  2011-03-22       Impact factor: 2.570

View more
  2 in total

Review 1.  Mixed connective tissue disease after thymectomy in refractory myasthenia gravis.

Authors:  Alexandra Kobza; Marissa Keenan; Catherine Ivory
Journal:  Rheumatol Int       Date:  2021-08-25       Impact factor: 3.580

Review 2.  Association Between Myasthenia Gravis and Systemic Lupus Erythematosus as a Comorbid State.

Authors:  Moeez Ali; Mohamed Riad; Prakash Adhikari; Sanket Bhattarai; Ashish Gupta; Eiman Ali; Jihan A Mostafa
Journal:  Cureus       Date:  2021-04-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.